



**Contact:**  
Tiana DiMichele  
Trimel Pharmaceuticals  
tdimichele@trimelpharmaceuticals.com  
(416) 679-0822

## **TRIMEL TO PRESENT AT THE 2015 BLOOM BURTON & CO. HEALTHCARE INVESTOR CONFERENCE**

**Toronto, Canada, April 13, 2015** – Trimel Pharmaceuticals Corporation (TSX:TRL) today announced that management is scheduled to present an overview of the Company at the 2015 Bloom Burton & Co. Healthcare Investor Conference at the Sheraton Centre Toronto Hotel on May 4, 2015 at 3:00 p.m. Eastern Time.

The Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested in the latest developments in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from the premier Canadian publicly traded and private companies through presentations and private meetings.

### **About Trimel**

Trimel is a Canadian specialty pharmaceutical company focused on bringing innovative products to market that improve the patient experience and produce strong investor returns.

Trimel markets ESTRACE® in Canada, a product indicated for the symptomatic relief of menopausal symptoms. NATESTO™, a product utilizing Trimel's licensed nasal gel technology, is the first testosterone nasal gel filed in Canada for approval, and is the first and only testosterone nasal gel approved and launched in the United States for replacement therapy in adult males diagnosed with hypogonadism. The commercial rights to NATESTO™ in the United States and Mexico have been licensed by Trimel to an affiliate of Endo International plc.

For more information, please visit [www.trimelpharmaceuticals.com](http://www.trimelpharmaceuticals.com).

###